ArticleCirculation reports2026
Geographical Disparities in the Detection and Certification of Systemic Amyloidosis in Japan: A Nationwide Registry Analysis, 2015-2024.
Article in Circulation reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Systemic amyloidosis has long been considered a rare disease, yet its nationwide epidemiology in Japan remains incompletely characterized, particularly with respect to geographical variation. Methods and Results: We analyzed publicly available data from Japan's national intractable disease registry (Designated Disease 28: systemic amyloidosis), which includes systemic AL/AH amyloidosis, wild-type and variant transthyretin amyloidosis, and other hereditary systemic forms, from 2015 to 2024. Annual prefecture-level counts of certified patients were extracted. Population-adjusted rates were calculated as the number of patients per 10,000 population using the 2020 national census as a fixed denominator. The total number of registered patients increased from 2,304 in 2015 to 8,168 in 2024, representing a 3.5-fold rise. The nationwide population-adjusted rate increased from 0.18 to 0.65 per 10,000 population. Marked geographical disparities were observed, with a pronounced west-east gradient and consistently higher rates in western Japan. In 2024, Oita Prefecture had the highest rate (2.2 per 10,000 population), followed by Kumamoto, Kochi, Nagano, Ehime, and Fukuoka. Conclusions: Registered systemic amyloidosis cases in Japan increased substantially over the past decade, particularly after the approval of tafamidis for transthyretin amyloid cardiomyopathy in 2019. The persistent geographical disparities may reflect differences in diagnostic practice and certification processes rather than true variation in disease prevalence, suggesting that systemic amyloidosis may remain incompletely recognized nationwide.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.